N. Mohedano

发表

Phase II trial of gemcitabine/doxorubicin/paclitaxel administered every other week in patients with metastatic breast cancer.

M. Dueñas, P. Sánchez‐Rovira, A. Lozano, 2000, Clinical breast cancer.

Phase I study concomitant gemcitabine (G) with radiotherapy (RT) in stage III NSCLC

P. Sánchez‐Rovira, R. Dueñas, A. Lozano, 1999 .

Response Assessment of 223Ra Treatment: Should a Fluorocholine PET/CT Be Performed?

A. M. G. Vicente, Á. Castrejón, N. Mohedano, 2017 .

Triplet chemotherapy combination with gemcitabine, cisplatin and ifosfamide in patients with advanced non-small-cell lung cancer: phase II study.

M. A. Moreno, P. Rovira, N. Mohedano, 2003 .

159 Phase II trial of gemcitabine in combination with cisplatin and ifosfamide in advanced non-small cell lung cancer (NSCLC)

P. Sánchez‐Rovira, M. A. Moreno, A. Lozano, 1997 .

Safety and effectiveness of vinflunine in patients with metastatic transitional cell carcinoma of the urothelial tract after failure of one platinum-based systemic therapy in clinical practice

I. Chirivella, G. De Velasco, D. Castellano, 2014, BMC Cancer.

Preliminary results from an early phase II combination of gemcitabine and taxol in metastatic breast cancer

P. Sánchez‐Rovira, M. A. Moreno, A. Lozano, 1997 .

An Unusual Metastatic Renal Cell Carcinoma with Maintained Complete Response to Sunitinib Treatment

E. Holgado, L. Chara, N. Mohedano, 2011, Case Reports in Oncology.

Biweekly gemcitabine, doxorubicin, and paclitaxel as first-line treatment in metastatic breast cancer. Final results from a phase II trial.

E. Carrasco, P. Sánchez‐Rovira, R. Dueñas, 2001, Oncology.

Neoadjuvant gemcitabine therapy for breast cancer.

P. Sánchez‐Rovira, R. Dueñas, A. Lozano, 2002, Clinical breast cancer.